LDL-C is considered to be the major lipid risk factor and the main target of lipid-lowering therapy. Nevertheless, as all potentially atherogenic lipoprotein particles contain only one molecule of ...

Results from the PURSUIT Phase IIb trial for AstraZeneca’s (AZN) AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant ...

“You are going to die young.” The first time I heard those six words, they were jarring. And I chuckle when I hear them.

In patients with cardiovascular disease or who are at high risk for CVD, lerodalcibep significantly decreases LDL-C. Lerodalcibep significantly decreases low-density lipoprotein cholesterol (LDL-C) in ...

Findings showed the trial met the primary endpoint, with enlicitide demonstrating a statistically significantly meaningful reduction in LDL-C compared with placebo. Topline data were announced from a ...

However, the association between familial hypercholesterolemia variants and coronary heart disease slightly weakened after adjusting for baseline low-density lipoprotein cholesterol (LDL-C) level and ...

A greater reduction LDL-C was seen for combo therapy; reductions also seen in all-cause mortality, major adverse CV events, stroke incidence. HealthDay News — Combination lipid-lowering therapy (LLT) ...

Despite recommendations, less than 45 percent of adults younger than 40 years with an elevated low-density lipoprotein cholesterol (LDL-C) level of 190 mg/dL or greater receive a prescription for a ...

Cholesterol is a fatty substance found in the blood and is essential for building healthy cells. However, not all cholesterol is created equal. LDL-C is considered harmful because it transports ...

Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio ® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy ...

Atherogenic lipoprotein particles can vary considerably in their cholesterol content, but each particle contains only one molecule of apoB-100 (or simply apoB). As a result, serum concentration of ...